{"id":"phase-b-triplixam-elestar-hct","safety":{"commonSideEffects":[{"rate":null,"effect":"Peripheral edema"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Hyperuricemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The combination product contains three antihypertensive agents working synergistically: a calcium channel blocker (diltiazem or similar) that reduces vascular smooth muscle contraction, an ARB (likely valsartan or similar) that blocks angiotensin II-mediated vasoconstriction and sodium retention, and hydrochlorothiazide (HCT), a thiazide diuretic that reduces blood volume and sodium levels. This triple mechanism provides additive blood pressure reduction for patients requiring intensive antihypertensive therapy.","oneSentence":"Triplixam/Elestar HCT is a fixed-dose combination that lowers blood pressure through multiple mechanisms: calcium channel blockade, angiotensin II receptor antagonism, and thiazide diuretic action.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:35:55.673Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension (marketed formulation for blood pressure control)"}]},"trialDetails":[{"nctId":"NCT06275763","phase":"PHASE4","title":"Optimal Medical Treatment of Difficult-to-treat Hypertension","status":"UNKNOWN","sponsor":"National Institute of Cardiology, Warsaw, Poland","startDate":"2023-10-20","conditions":"Hypertension","enrollment":2500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Triple Single Pill Combination: Triplixam / Elestar HCT"],"phase":"marketed","status":"active","brandName":"Phase B: Triplixam / Elestar HCT","genericName":"Phase B: Triplixam / Elestar HCT","companyName":"National Institute of Cardiology, Warsaw, Poland","companyId":"national-institute-of-cardiology-warsaw-poland","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Triplixam/Elestar HCT is a fixed-dose combination that lowers blood pressure through multiple mechanisms: calcium channel blockade, angiotensin II receptor antagonism, and thiazide diuretic action. Used for Hypertension (marketed formulation for blood pressure control).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}